Influenza and other Respiratory Viruses

Our drug has potent antiviral activity against many respiratory viruses including influenza, respiratory syncytial virus (RSV), metapneumovirus (HMPV) and hantavirus.

With potent activity against at least four different respiratory viruses, our technology has the potential to be useful in treating a broad spectrum of respiratory viral infections and also promises the ability to treat individuals who suffer co-infection with two or more different sensitive respiratory viruses. REPLICor’s compounds have also showed potent broad-spectrum activity in vitro and in vivo against many different viruses (click here for a list).

Influenza, Avian Flu and other newly emergent flu strains (e.g .Swine flu)

REPLICor’s amphipathic DNA polymer technology has been shown to be broadly active against numerous influenza strains, including avian flu (A/H5N1), numerous H1N1 strains as well as influenza strains resistant to currently marketed drugs for the treatment of influenza in human patients (see table below).  Moreover, in preclinical development, our early stage compounds have been shown active against influenza infection in vivo either by aerosol or parenteral administration.  REPLICor believes that its technology can be of great benefit in the fight against newly emergent influenza strains.

Influenza strains responsive to treatment in vitro:

Respiratory Syncytial Virus

REPLICor’s technology also has broad activity in numerous RSV strains in vitro and in preclinical development, early stage compounds have shown well tolerated and substantial antiviral activity against RSV infection in vivo. RSV causes upper and lower respiratory tract infections. According to the American Medical Association, an increasing number of children are being hospitalized for bronchiolitis, often caused by RSV infection.  In the elderly population, RSV infection has been recently recognized to be very similar in severity to influenza virus infection.

Human Metapneumovirus

REPLICor’s technology has also shown to be active against several HMPV strains in vitro and likely will also be active against infections in vivo as well. HMPV is another causative agent of upper and lower respiratory tract infections, especially in infants.

Hantavirus

Hantavirus pulmonary syndrome is a deadly disease transmitted by infected rodents through urine, droppings, or saliva. Humans can contract the disease when they breathe in aerosolized virus.  Our drug has been shown to be active in vitro against hantavirus.